Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 13, Issue 2, 2014, Pages 164-171

  Cory, Theodore J ^a,b   Birket, Susan E ^a,c   Murphy, Brian S ^a   Hayes, Don ^d   Anstead, Michael I ^a   Kanga, Jamshed F ^a   Kuhn, Robert J ^a   Bush, Heather M ^a   Feola, David J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Azithromycin; Cystic fibrosis; Macrophage phenotype

Indexed keywords

ANTIINFECTIVE AGENT; AUTACOID; AZITHROMYCIN; IMMUNOGLOBULIN RECEPTOR;

ADULT; CHILD; CYSTIC FIBROSIS; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION TEST; MACROPHAGE ACTIVATION; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CYSTIC FIBROSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MALE; PHENOTYPE; RECEPTORS, IMMUNOLOGIC; RESPIRATORY FUNCTION TESTS;

EID: 84895069717     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.08.007     Document Type: Article

References (30)

1. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med Oct 15 2003, 168(8):918-951.
2. McKeon D.J., Cadwallader K.A., Idris S., Cowburn A.S., Pasteur M.C., Barker H., et al. Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation. Eur Respir J Jun 2010, 35(6):1264-1272.
3. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet Sep 28 2002, 360(9338):978-984.
4. Saiman L., Anstead M., Mayer-Hamblett N., Lands L.C., Kloster M., Hocevar-Trnka J., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA May 5 2010, 303(17):1707-1715.
5. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA Oct 1 2003, 290(13):1749-1756.
6. Saiman L., Mayer-Hamblett N., Campbell P., Marshall B.C. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med Oct 15 2005, 172(8):1008-1012.
7. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax Mar 2002, 57(3):212-216.
8. Murphy B.S., Sundareshan V., Cory T.J., Hayes D., Anstead M.I., Feola D.J. Azithromycin alters macrophage phenotype. J Antimicrob Chemother Mar 2008, 61(3):554-560.
9. Feola D.J., Feola B.A., Cory T.J., Birket S.E., Hoy H., Hayes D., et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob Agents Chemother Jun 2010, 54(6):2437-2447.
10. Murphy B.S., Bush H.M., Sundareshan V., Davis C., Hagadone J., Cory T.J., et al. Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros Sept 2010, 9(5):314-322.
11. Ringnér M. What is principal component analysis?. Nat Biotechnol 2008, 26(3):303-304.
12. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol Dec 2004, 25(12):677-686.
13. Hartl D., Griese M., Kappler M., Zissel G., Reinhardt D., Rebhan C., et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol Jan 2006, 117(1):204-211.
14. Mege J.L., Mehraj V., Capo C. Macrophage polarization and bacterial infections. Curr Opin Infect Dis Jun 2011, 24(3):230-234.
15. Daley J.M., Brancato S.K., Thomay A.A., Reichner J.S., Albina J.E. The phenotype of murine wound macrophages. J Leukoc Biol Jan 2010, 87(1):59-67.
16. Meyer M. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009, 41(5):590-602.
17. Naura A.S., Zerfaoui M., Kim H., Abd Elmageed Z.Y., Rodriguez P.C., Hans C.P., et al. Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation. J Immunol Sep 1 2010, 185(5):3076-3085.
18. Mori M., Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun Sep 7 2000, 275(3):715-719.
19. Munder M., Eichmann K., Moran J.M., Centeno F., Soler G., Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol Oct 1 1999, 163(7):3771-3777.
20. Song E., Ouyang N., Horbelt M., Antus B., Wang M., Exton M.S. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol Aug 25 2000, 204(1):19-28.
21. Gaggar A., Li Y., Weathington N., Winkler M., Kong M., Jackson P., et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 2007, 293(1):L96-L104.
22. Ratjen F., Hartog C., Paul K., Wermelt J., Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 2002, 57(11):930-934.
23. Sagel S.D., Kapsner R.K., Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005, 39(3):224-232.
24. Cory T.J., Birket S.E., Murphy B.S., Mattingly C., Breslow-Deckman J.M., Feola D.J. Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa. J Antimicrob Chemother April 1 2013, 68(4):840-851.
25. Lawrence D.A. Latent-TGF-beta: an overview. Mol Cell Biochem Mar 2001, 219(1-2):163-170.
26. Harris W.T., Muhlebach M.S., Oster R.A., Knowles M.R., Clancy J., Noah T.L. Plasma TGF-β1 in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy. Pediatr Pulmonol 2011, 46(7):688-695.
27. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol Nov 15 2006, 177(10):7303-7311.
28. Prasse A., Pechkovsky D.V., Toews G.B., Jungraithmayr W., Kollert F., Goldmann T., et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med Apr 1 2006, 173(7):781-792.
29. Pechkovsky D.V., Prasse A., Kollert F., Engel K.M., Dentler J., Luttmann W., et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol Oct 2010, 137(1):89-101.
30. Hauser A.R., Jain M., Bar-Meir M., McColley S.A. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011, 24(1):29-70.